LLY

1,006.06

+1.27%↑

JNJ

209.91

+1.6%↑

ABBV

223.8

-0.55%↓

UNH

336.55

+2.68%↑

AZN

90.26

-1.28%↓

LLY

1,006.06

+1.27%↑

JNJ

209.91

+1.6%↑

ABBV

223.8

-0.55%↓

UNH

336.55

+2.68%↑

AZN

90.26

-1.28%↓

LLY

1,006.06

+1.27%↑

JNJ

209.91

+1.6%↑

ABBV

223.8

-0.55%↓

UNH

336.55

+2.68%↑

AZN

90.26

-1.28%↓

LLY

1,006.06

+1.27%↑

JNJ

209.91

+1.6%↑

ABBV

223.8

-0.55%↓

UNH

336.55

+2.68%↑

AZN

90.26

-1.28%↓

LLY

1,006.06

+1.27%↑

JNJ

209.91

+1.6%↑

ABBV

223.8

-0.55%↓

UNH

336.55

+2.68%↑

AZN

90.26

-1.28%↓

Search

Harvard Bioscience Inc

Chiusa

SettoreSettore sanitario

0.73 -3.95

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

0.72

Massimo

0.76

Metriche Chiave

By Trading Economics

Entrata

1.1M

-1.2M

Vendite

141K

21M

Margine di Profitto

-5.978

Dipendenti

330

EBITDA

1M

1.2M

Raccomandazioni

By TipRanks

Raccomandazioni

Acquista

Previsioni per 12 mesi

+163.16% upside

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

8.2M

34M

Apertura precedente

4.68

Chiusura precedente

0.73

Notizie sul Sentiment di mercato

By Acuity

26%

74%

84 / 374 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Weak Bearish Evidence

Harvard Bioscience Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

10 dic 2025, 22:02 UTC

Utili

Synopsys Sees Strong 2026 as Ansys Acquisition Boosts 4Q Revenue

10 dic 2025, 21:46 UTC

Utili

Adobe Expects Double-Digit Recurring Revenue Growth Next Year

10 dic 2025, 23:52 UTC

Acquisizioni, Fusioni, Takeovers

Paramount Sends Letter to Warner Bros. Shareholders Saying Its Offer Is 'Superior' -- Barrons.com

10 dic 2025, 23:43 UTC

Discorsi di Mercato

Nikkei May Rise After Fed Rate Cut -- Market Talk

10 dic 2025, 23:36 UTC

Discorsi di Mercato

Gold Consolidates as Traders Digest FOMC Decision -- Market Talk

10 dic 2025, 23:20 UTC

Utili

Oracle Reports $16.1 Billion in Revenue, Narrowly Missing Forecasts -- 2nd Update

10 dic 2025, 23:15 UTC

Utili

Synopsys Targets Double-Digit Growth Following Ansys Acquisition -- Interview

10 dic 2025, 22:59 UTC

Discorsi di Mercato
Utili
Acquisizioni, Fusioni, Takeovers

Adobe Expects Semrush Deal to Bring in New Users -- Market Talk

10 dic 2025, 22:45 UTC

Discorsi di Mercato

Coca-Cola's New CEO Pick Looks A Lot Like The Last One -- Market Talk

10 dic 2025, 22:40 UTC

Utili

Synopsys Stock Rises on Earnings Beat, Higher Guidance -- Barrons.com

10 dic 2025, 22:06 UTC

Acquisizioni, Fusioni, Takeovers

Paramount Sends Letter to Warner Bros. Shareholders Saying Their Offer Is 'Superior' -- Barrons.com

10 dic 2025, 22:06 UTC

Utili

Oracle Reports Mixed Earnings. The Stock Is Falling. -- Barrons.com

10 dic 2025, 22:02 UTC

Utili

Synopsys Stock Rises on Earnings Beat, Higher Guidance -- Barrons.com

10 dic 2025, 22:00 UTC

Utili

Oracle Reports $16.1 Billion in Revenue, Narrowly Missing Forecasts -- Update

10 dic 2025, 21:53 UTC

Utili

Adobe Earnings Show 'Rapid Adoption' of AI Tools. The Stock Is Up. -- Barrons.com

10 dic 2025, 21:50 UTC

Acquisizioni, Fusioni, Takeovers

Investors Bet That a Higher Bid for Warner Is Coming -- Update

10 dic 2025, 21:50 UTC

Discorsi di Mercato
Utili
Acquisizioni, Fusioni, Takeovers

Financial Services Roundup: Market Talk

10 dic 2025, 21:50 UTC

Discorsi di Mercato

Health Care Roundup: Market Talk

10 dic 2025, 21:50 UTC

Discorsi di Mercato

Auto & Transport Roundup: Market Talk

10 dic 2025, 21:45 UTC

Acquisizioni, Fusioni, Takeovers

Paramount Sends Letter to Warner Bros. Shareholders Saying Their Offer Is 'Superior' -- Barrons.com

10 dic 2025, 21:33 UTC

Utili

Oracle Reports $16.1 Billion in Revenue, Narrowly Missing Forecasts -- WSJ

10 dic 2025, 21:32 UTC

Utili

Oracle Reports Mixed Earnings. The Stock Is Falling. -- Barrons.com

10 dic 2025, 21:28 UTC

Acquisizioni, Fusioni, Takeovers

Sverica Capital Management Announces Sale of Coastal Cloud Holdings to Tata Consultancy Services for $700M

10 dic 2025, 21:25 UTC

Utili

Adobe Earnings Show 'Rapid Adoption' of AI Tools. The Stock Is Up. -- Barrons.com

10 dic 2025, 21:18 UTC

Acquisizioni, Fusioni, Takeovers

Paramount Skydance: Company Has Air Tight Financing to Deliver on Warner Bros. Offer >PSKY

10 dic 2025, 21:16 UTC

Utili

Oracle Reports Mixed Earnings. The Stock is Falling. -- Barrons.com

10 dic 2025, 21:15 UTC

Acquisizioni, Fusioni, Takeovers

Paramount Skydance: Public Offer for Warner Bros. Delivers Superior Value, Faster, More Certain Path to Completion

10 dic 2025, 21:15 UTC

Utili

Oracle: 'Sold Ampere Because We No Longer Think It Is Strategic for Us to Continue Designing, Manufacturing and Using Our Own Chips in Our Cloud Datacenters' >ORCL

10 dic 2025, 21:14 UTC

Utili

Oracle 2Q Non-GAAP Operating Income Was $6.7 B >ORCL

10 dic 2025, 21:14 UTC

Utili

Oracle 2Q GAAP Operating Income Was $4.7 B >ORCL

Confronto tra pari

Modifica del prezzo

Harvard Bioscience Inc Previsione

Obiettivo di Prezzo

By TipRanks

163.16% in crescita

Previsioni per 12 mesi

Media 2 USD  163.16%

Alto 2 USD

Basso 2 USD

Basato su 1 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Harvard Bioscience Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

1 ratings

1

Acquista

0

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

0.3 / 0.3401Supporto e resistenza

A breve termine

Weak Bearish Evidence

A termine intermedio

No Evidence

A lungo termine

No Evidence

Sentiment

By Acuity

84 / 374 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Prove rialziste

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Harvard Bioscience Inc

Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings. It also provides preclinical products that includes platform to assess physiological data from organisms for research, drug discovery, and drug development services comprising implantable and externally worn telemetry systems for use in research to collect cardiovascular, central nervous system, respiratory, and metabolic data; behavioral products; isolated organ and surgical products, instruments and accessories for tissue, and organ-based lab research, including surgical products, infusion systems, and behavior research systems; turn-key respiratory system solutions, including plethysmograph chambers, data acquisition hardware, physiological signal analysis software, and final report generation; inhalation and exposure systems; and GLP-capable data acquisition and analysis systems. The company markets its products through sales organizations, websites, and distributors to research scientists in pharmaceutical and biotechnology companies, universities, hospitals, and government laboratories; and contract research organizations and academic labs. It primarily sells its products under Harvard Apparatus, DSI, Buxco, Biochrom, BTX, Heka, Hugo Sachs, Multichannel Systems MCS GmbH, and Panlab brands. Harvard Bioscience, Inc. was founded in 1901 and is based in Holliston, Massachusetts.
help-icon Live chat